İntrahepatik kolanjiyosellüler karsinomlarda transarteriyel radyoembolizasyon tedavisinin sağkalım üzerine etkisi


Ballı H. T. , Güney İ. B. , Pişkin F. C. , Aikimbaev K.

cukurova medical journal, vol.44, no.4, pp.1379-1385, 2019 (Journal Indexed in ESCI)

  • Publication Type: Article / Article
  • Volume: 44 Issue: 4
  • Publication Date: 2019
  • Title of Journal : cukurova medical journal
  • Page Numbers: pp.1379-1385

Abstract

Abstract Öz Purpose: The aim of this study was to present the survival analyses of patients with intrahepatic cholangiocellular carcinoma who are ineligible forsurgical treatment and treated with transarterial radioembolization. Materials and Methods: Twenty-eight patients with intrahepatic cholangiocellular carcinoma who were not eligible for surgical treatment were included in this study. All patients were treated by transarterial radioembolization. The survival time of the patients who were followed up after diagnosis was recorded. KaplanMeier survival analysis was used to calculate survival. Results: The mean age was 60.46 years. While minimum age of patients was 36 years, maximum age of patients 84 years. The median follow-up was 14 months (min:3, max:33). The median survival time of the patients was 22 months (min:3 months, max:33 months). In addition, the survival time of patients who received chemotherapy and patients who did not receive chemotherapy, patients with solitary tumor, patients with multifocal tumor, patients with tumor unilobar and patients with bilobar were calculated and no significant difference was found between the groups. Conclusion: Although modern chemotherapy has increased this survival rate, it has not been able to increase the median survival beyond 12 months. When these data are taken into consideration, it is seen that transarterial radioembolization treatment prolongs survival.